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2352-3042/Copyright ª 2014, ChongqAbstract Engineered functional organs or tissues, created with autologous somatic cells and
seeded on biodegradable or hydrogel scaffolds, have been developed for use in individualswith tis-
sue damage suffered fromcongenital disorders, infection, irradiation, or cancer. However, in those
patients, abnormal cells obtainedbybiopsy fromthe compromised tissuecould potentially contam-
inate the engineered tissues. Thus, an alternative cell source for construction of the neo-organ or
functional recovery of the injured or diseased tissues would be useful. Recently, we have found
stem cells existing in the urine. These cells are highly expandable, and have self-renewal capacity,
paracrine properties, and multi-differentiation potential. As a novel cell source, urine-derived
stem cells (USCs) provide advantages for cell therapy and tissue engineering applications in regen-
eration of various tissues, particularly in the genitourinary tract, because they originate from the
urinary tract system. Importantly, USCs can be obtained via a non-invasive, simple, and low-cost
approach and induced with high efficiency to differentiate into three dermal cell lineages.
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Urine stem cells for regenerative medicine 9Introduction
Stem cells have shown potential as a therapeutic strategy
for repair of various tissues, including genitourinary organs.
Stem cell-based therapy for genitourinary tissue repair is
most relevant to congenital conditions or disorders such as
radiation damage, chronic inflammatory diseases, and tu-
mors. Multiple types of stem cells have been used in pre-
clinical animal models to repair or regenerate tissue,
employing either trans-differentiation or paracrine effects
to stimulate endogenous cells participating in tissue
regeneration. These stem cells include pluripotent stem
cells such as embryonic stem cells (ESCs); induced plurip-
otent stem cells (iPS),1 multipotent mesenchymal stem
cells (MSCs), including bone marrow-derived mesenchymal
stromal cells (BMSC)2e6; adipose-derived stem cells (ASCs)7;
hair follicle stem cells8; and amniotic fluid stem cells.9
We recently found that a subpopulation of cells isolated
from urine possess biological characteristics with stem cell
characteristics, i.e. clonogenicity, cell growth patterns,
expansion capacity, cell surface marker expression profiles,
multipotent differentiation, pro-angiogenic paracrine ef-
fects, immune-modulatory properties, and easily-induced
pluripotent stem cells. Thus, we have termed these cells
“urine-derived stem cells” or USCs.10e12 These stem cells
can be obtained from humans and different animal species,
such as monkeys, pigs, and rabbits. Although stem cellsFigure 1 Possible sources of endogenous renal stem cells in the
renal stem cells, which are possibly the sources of urine-derived st
stem cells.make up a small proportion of the total cell population,
they play an important role in replacing aged, injured, and
diseased cells and promoting tissue regeneration from or-
gans where they originate. USCs consistently expressed
MSC/pericyte markers and some key cell surface markers,
but not hematopoietic stem cell markers (except for MHC-
1), endothelial cell markers (CD31), or human leukocyte
antigen (locus) DR (HLA-DR). Compared to other MSCs, USCs
have several advantages: i) they can be obtained regardless
of a person’s age, gender, or health condition (except in
those urinary tract infection and anuria); ii) the cells can be
collected using a simple, safe, low-cost and non-invasive
procedure; iii) it is easier to isolate pure stem cells,
which do not require an enzyme digestion process; iv) the
cells display telomerase activity so that they are able to
generate more cells, but not teratomas or tumors; and v)
they differentiate into podocytes, smooth muscle, and
endothelial and urothelial cells with higher efficiency.10e12Origin of USCs
The source of endogenous stem cells in the kidney may be
the renal tubules or the papilla. Glomerular parietal
epithelial cells function as stem cells in the glomeruli
(Fig. 1), displaying self-renewal properties and the poten-
tial to give rise to podocytes and proximal tubular cells.13e28kidney. (A) The dotted area depicts the potential existence of
em cells. (B) A detailed depiction of possible locations of urine
10 D. Zhang et al.The epithelialmesenchymal transition (EMT) is a process
by which epithelial cells lose their cell polarity to become
mesenchymal stem cells; these multipotent stromal cells
can differentiate into a variety of cell types in renal repair
and regeneration. Parietal cells are commonly obtained
from kidney tissue biopsies, but the isolation of pure pari-
etal cells is difficult.29,30
Identifying the origin of USCs will lead to a better un-
derstanding of the biological impact of this multipotent
MSC population in the urinary tract system. There is strong
evidence that USCs are most likely from glomerular parietal
epithelial cells. USCs isolated from urine obtained from the
upper urinary tract are similar to voided USCs in
morphology, cell phenotypes, growth pattern, and differ-
entiation capacity, suggesting that the voided USCs origi-
nate from the upper urinary tract.11,31 In addition, urine-
derived cells from women who had received transplanted
kidneys from male donors contained the Y chromosome and
expressed normal renal cell markers (PAX2 and PAX8),
podocytes, glomerular parietal cells, and specific gene and
protein markers (synaptopodin and podocin),13e30,32e36
suggesting that USCs most likely originate from the kid-
ney. Furthermore, USCs expressed CD146þ/CD31 at a rate
similar to that expressed in parietal cells and podocytes in
glomerulus, while renal tubule epithelial cells, bladder and
ureter urothelial and smooth muscle cells did not, implying
that USCs are likely transitional cells at the parietal cell/
podocyte interface originating from renal tissue10 (Fig. 2).
Self-renewal of USCs
USCs can be obtained from voided urine and can generate a
large number of cells from a single clone10,37 (Fig. 3). These
cells form homogenous cell types and possess highly pro-
liferative capacity because they maintain higher telome-
rase activity and longer telomere length compared to other
types of MSCs10 (Table 1). Upto 75% of USCs collected from
middle-aged individuals expressed telomerase activity
(USCs-TAþ) and retained long telomere length,38 but USCs-
TAþ decline to 50e60% of the USCs in people 50 years old orFigure 2 Renal cells, including parietal cells, podocytes, and
renal tubule epithelial cells, are shed off into the urine in
normal physiologic conditions.older. USCs-TAþ can be maintained for upto 20 passages
with 67 population doublings, indicating that a single USC
can generate upto 267 cells within 14 weeks. In contrast,
USCs-TA grow only for 8-10 passages with 34 population
doublings. Importantly, either USCs-TAþ or USCs-TA display
normal karyotypes in culture medium even after several
passages. They did not form teratomas 3 months after renal
subcapsular cell implantation.38 We can now obtain 100-140
USC clones/24 h urine from each individual.39 About
1.4  109 cells are needed for potential use in bladder
reconstruction with cell-seeded technology.40 Thus, two
urine samples containing 20e30 USC clones in 400 ml can
provide ample cells (1.5  109 USCs at p4) within 4e5 weeks
to be used in cell-based therapy for genitourinary tissue or
organ repair.Multipotent differentiation of USCs
USCs can differentiate in vitro into multi-potential cells.
After being induced in the appropriate culture condition,
each type of differentiated USC expressed specific markers
at the gene, protein, and cellular levels of osteogenic,41
chondrogenic and adipogenic myogenic,42 neurogenic43 and
endothelial cell types,10 respectively. Following implanta-
tion in vivo, induced USCs can form functional bone, carti-
lage, fat, muscle, endothelium, and urothelium tissue.10
For ureter, bladder, or urethral tissue engineering, uro-
thelial, endothelial, and smooth muscle cells are needed
for creating urothelial mucosa, blood vessels, and muscle
wall. However, a challenge in urological tissue regeneration
is generating urothelial cells from BMSCs or ASCs Although
BMSCs, the most commonly used MSC source, can efficiently
differentiate into smooth muscle and endothelial
cells,5,6,44e52 only 5e10% of BMSCs can give rise to the cells
expressing urothelial gene and protein markers.5 One of the
most likely reasons for this is that true stem cells in bone
marrow stromal cells are very rare, depending on donor age
(1/104 cells in newborns, but 1/106 in older individuals). In
addition, it is very difficult to isolate pure stem cells from
the large amount of somatic cells. Furthermore, it is less
likely to induce stromal cells (mesodermal) to differentiate
into urothelial cells (endodermal).
Using the same inductive medium as in the BMSC study,53
we found that 60%e70% of USCs differentiated into cells
expressing uroepithelial cell-specific genes and protein
markers (uroplakin-Ia/III), and had urothelial barrier func-
tion and tight junction ultrastructures. Urothelial differ-
entiated USCs also expressed the genes and proteins for ZO-
1, E-cadherin, and cingulin (associated with tight junctions)
in a dose- and time-dependent manner. The barrier func-
tion of induced USCs reaches a maturity similar to that of
urothelial cells isolated from bladder tissue 14 days after
induction, significantly better than non-induced USCs,
indicating that USCs possess stem cell plasticity.10
USCs can efficiently give rise to functional cells of the
smooth muscle cell lineage. Myogenically-differentiated
USCs expressed smoothelin, desmin, myosin, a-SM actin,
and calponin at both the gene and protein levels. The mRNA
and protein levels of these markers increased significantly
with time in differentiation media. Functional studies
demonstrated that these differentiated USCs have similar
Figure 3 Cell proliferation, differentiation, and trophic factor secretion by urine-derived stem cells in vitro.
Urine stem cells for regenerative medicine 11contractile properties as healthy smooth muscle cells
in vitro. Myogenically-differentiated USCs formed multiple
layers of smooth muscle cells beneath UC layers when
subcutaneously implanted in a nude mouse model. The
smooth muscle cells stained positively for a-SMA, desmin,
and myosin. Scaffolds containing urothelial differentiated
USCs generated stratified layers in vivo and stained positive
for uroplakin-Ia and uroplakin-III (urothelial markers) and
epithelial cell markers (Ck 7, Ck13, Ck20 and AE1/AE3).10,11
We found that USCs differentiate into cells of the
endothelial lineage when grown in endothelial differentia-
tion medium containing 2 ng/ml VEGF for 12 days. Early
in vitro vessel-forming was displayed 18 h after differen-
tiated USCs (5  103 cells) were seeded onto Matrigel. The
differentiated cells began to express the specific gene and
protein markers of endothelial cells (CD31, vWF, KDR, FLT-
1, FLT-1, eNOS and VE-cadherin). Induced USCs demon-
strated intense immunofluorescent staining for these
markers compared to non-differentiated USCs. Importantly,
USCs can be efficiently differentiated into endothelial cells
with barrier function. Neovessel formation occurred 4
weeks after induced USCs were subcutaneously implanted
in an athymic mouse model.10
Immunoregulatory property of USCs
Regulatory T cells play an important role in induction of
peripheral tolerance, inhibition of pro-inflammatory im-
mune responses, and decreased immune reactions. USCs
can impart profound immunomodulatory effects, by inhib-
iting proliferation of peripheral blood mononuclear cells
(PBMNC) and T and B cells, and secreting interleukin (IL)-6
and IL-8.54PBMNCs proliferated when mixed with other cells due to
immune stimulation.55 However, PBMNC concentrations in
USC wells were much lower than in BMSC culture wells.
BrdU colorimetric ELISAs showed there was less BrdU
labeled into the USC PBMNC mixed culture wells compared
to BMSC culture wells. CD80 and CD86 expressed on the
surface of antigen-presenting cells interact with cytotoxic
T lymphocyte antigen-4 expressed on activated T cells and
mediate critical T cell inhibitory signals. Flow cytometry
showed that 3.35% of the BMSCs were positive for CD80
(versus 1.05% of USCs), and 1.3% of the BMSCs were positive
for CD86 (versus 0.55% of USCs). Human cytokine release
arrays showed that IL-6 and IL-8 concentrations were
elevated after stimulation by PBMNCs in USC supernatant,
which is higher than BMSC supernatant. IL-6 and IL-8 might
be the main immunomodulatory cytokines to target in
future studies aimed at preventing and treating diabetic
bladder tissue lesions, other immune system disorders, or
rejection of transplanted organs.
Trophic factors secreted by USCs and
exogenous growth factors
USCs can secrete angiogenic growth factors and cyto-
kines,56,57 but require a favorable microenvironment to do
so. We demonstrated that use of genetically modified stem
cells via transfection of the VEGF gene significantly pro-
moted myogenic differentiation of USCs and induced
angiogenesis and innervation.58 However, virally delivered
VEGF caused severe side effects in our animal model,
including hyperemia, hemorrhage, and even death.42 Thus,
a safer approach is needed for stem cell therapy to increase
angiogenesis and promote muscle regeneration. Adding
Table 1 Comparison of USCs and other types of stem cells in genitourinary tissue repair.
Cell type/parameters MSCs USCs ESC/iPS cells Somatic cells from GU tissues
Original sites Bone marrow or fat tissues kidney EC, SMC and UC from bladder
Self-renewal and expansion
capability
Limited, PDw30, <passage 8 High, PD 60e70 > passage 15 Very high, PD > 200, Limited, PD < 30, passage <8
Multi-lineage differentiation
capability
Multipotent, but mainly limited
within mesodermal cell
lineages: i.e. ostocytes,
adipocytes, chondrocytes
Multipotent differentiation
potential; give rise to three
dermal cell lineages
Pluripotent (can form all
lineages of the body)
None
Urothelial and endothelial
differentiation capability
Low (<10%) High (60e85%) Low None
Telomerase activity (TA)/
telomere length
Cannot be detected Upto 75% USC clones possess TA
and relatively long telomeres
Possess TA and long telomeres None
Harvesting methods Invasive Non-invasive, simple, cost-low,
safe
Invasive to harvest somatic
cells for iPS cells
Invasive
Stem cell isolation Difficult Very easy Easy None
Number of stem cells harvested 1 MSC/104 bone marrow
stromal cells in a newborn, 1
MSC/106
100e140 USCs clones/24 h
urine in adult
Unknown
Angiogenic trophic factors Yes Yes Unknown Moderate
Immnuno-modulatory
properties
Yes Yes Unknown Moderate
Rejection after implanted
in vivo
No rejection reaction as allogenous or even xenogenous cells (e.g.
human BMSCs, USCs) implanted in rodent, rabbit, or canine models
Likely to be rejected No rejection as autogenous
cells
Teratoma formation or
oncogenic potential
No No Yes None
Preclinical Study in renal
insufficiency, ED, SUI,
bladder or urethral
reconstruction
Effective Effective None, due to safety concern Effective
References 26,53 11,12,31,37,39,42,72 70
Abbreviation: ESC, embryonic stem cell; GU, genitourinary; PD, population doubling; BMSC, bone marrow stem cell; MSC, mesenchymal stem cell; iPS, pluripotent stem cell; TA,
telomerase activity; USC, urine-derived stem cell; SMC, smooth muscle cell; UC, urothelial cell; EC, endothelial cell; ED, erectile dysfunction; SUI, stress urinary incontinence.
12
D
.
Z
h
a
n
g
e
t
a
l.
Urine stem cells for regenerative medicine 13exogenous angiogenic factors into biodegradable polymers
as delivery vehicles can be beneficial to promote regener-
ation and tissue healing.59 Alginate is one of the most
commonly used natural hydrogels as an aqueous drug
carrier for encapsulation because of its mild gelling condi-
tions and tunable microsphere characteristics. Alginate
microbeads also resist protein adsorption, making them
attractive for in vivo studies.60 Alginate microbeads deliver
molecules in a controlled fashion, which can stably release
active FGF-1 for at least 3 weeks in vitro. This sustained
release of FGF-1 promoted neovascularization in vivo
without any side effects.61e63 More recently, we found that
a combination of growth factors (VEGF, IGF-1, FGF-1, PDGF,
HGF and NGF) released locally from alginate microbeads
induced USCs to differentiate into a myogenic lineage,
enhanced revascularization and innervation, and stimu-
lated resident cell growth in vivo.42 In addition, when
cultured on 3D biomaterial, stem cells had significantly
enhanced cell viability, proliferation, and differentiation
in vitro; and promoted tissue formation in vivo, compared
to cells cultured on 2-dimensional plates.64
iPS cells reprogrammed from USCs
The ability to reprogram iPS cells from adult somatic cells
could promote broad biomedical applications of stem cells,
such as drug developments and tissue regeneration. Despite
successful converting to iPS cells from various types of so-
matic cells, the process is time-consuming and inefficient.
In our recent study, we created iPS cells from the urine of a
child with Duchenne muscular dystrophy.65 The cells found
in the patient’s urine were reprogrammed to iPS more
rapidly and with greater efficiency than fibroblasts or other
mesenchymal cells. Following the forced expression of the
four reprogramming factors oct4, sox2, klf4 and c-myc,
urine cells from a healthy volunteer and a patient with
Duchenne muscular dystrophy were successfully reprog-
rammed into iPS cells in 12 days, whereas it required more
than 3 weeks to reprogram human skin fibroblasts. Cells
harbored in the urine intrinsically expressed two canonical
reprogramming factors, c-myc and klf4, together with
highly active telomerase. The latter characteristic of urine
cells contributes to improved reprogramming efficiency.
Our data and other investigators’ studies66e70 demonstrate
the feasibility of rapid and efficient iPS cell generation
from a sample of human urine, suggesting potential thera-
peutic uses of patient- derived iPS cells both for the
treatment of various genetic defects via cell-based therapy
and for drug screening.
Applications of USCs in animal studies
Diabetic erectile dysfunction
As with other MSCs,44e52,71 we recently determined that
either human USCs or USCs genetically modified with FGF2
improved erectile dysfunction in a type 2 diabetic rat
model.56 USCs collected from human healthy donors and
were transfected with FGF2 (USCs-FGF2). The implanted
cells were injected into the cavernous tissue and tracked
1 and 4 weeks later. Implanted USCs or USCs-FGF2 hadsignificantly higher intracavernous pressure (ICP) and a
higher ratio of ICP to mean artery pressure 28 days after
ICP. Although few cells were detected within the implanted
sites, histological and Western blot analyses demonstrated
increased expression of endothelial and smooth muscle
markers within the cavernous tissue following USC or USC-
FGF2 injection. This study demonstrated that paracrine
effects of USCs or USCs-FGF2 induced improvement of
erectile function in type 2 diabetic rats by recruiting resi-
dent cells and increasing the endothelial expression and
amounts of smooth muscle.
Urinary incontinence
Impairment of sphincter muscles or their neural and
vascular support leads to stress urinary incontinence.57 To
determine the feasibility of using USCs, we studied the role
of USCs or USCs over-expression of human VEGF165 in
collagen-I gel on angiogenesis, cell survival, cell growth,
myogenic phenotype differentiation of the implanted cells,
and innervation following implantation in vivo. USCs were
infected with adenovirus containing the VEGF and green
fluorescent protein genes. A total of 5  106 cells, USCs
alone, USCs plus endothelial cells, or human skeletal
myoblasts (as control) suspended in collagen-I gel were
subcutaneously implanted into nude mice. Extensive
vascularization and more implanted cells was noted in
VEGF-expressing USCs groups compared to the non-VEGF
groups in vivo. Significantly more cells displaying endo-
thelial markers (CD 31 and von Willebrand’s factor) and
myogenic markers (myf-5, MyoD, and desmin), and regen-
erated nerve fibers displaying neural markers (S-100, GFAP
and neurofilament) were seen in grafts of VEGF-expressing
USCs. Improved angiogenesis by VEGF-expressing USCs
enhanced grafted cell survival, recruited resident cells, and
promoted myogenic phenotype differentiation of USCs and
innervation. This approach has important clinical implica-
tions for the development of cell therapies to treat stress
urinary incontinence.
To provide site-specific delivery and targeted release of
growth factors to implanted USCs, we prepared microbeads
of alginate containing growth factors.42 The growth factors
included VEGF, IGF-1, FGF-1, PDGF, HGF, and NGF. Radio-
labeled growth factors were loaded separately and used to
track in vitro release from the microbeads, as measured
with a gamma counter over 4 weeks. In a separate experi-
ment, in vitro endothelial differentiation of USCs via the
released VEGF released from the microbeads confirmed
that the released growth factors from the microbeads were
bioactive. Next, USCs and microbeads were mixed with the
collagen gel type 1 (2 mg/ml) and subcutaneously injected
into nude mice. Four weeks after subcutaneous injection,
grafted cell survival was improved and more cells expressed
myogenic and endothelial cell transcripts and markers
compared to controls. Compared to controls, we observed
more vessel formation and innervation in USCs combined
with the six growth factors and incorporated in microbeads.
In conclusion, a combination of growth factors released
locally from the alginate microbeads induced USCs to
differentiate into a myogenic lineage, enhanced revascu-
larization and innervation, and stimulated resident cell
growth in vivo. This approach could potentially be used for
14 D. Zhang et al.cell therapy in the treatment of stress urinary inconti-
nence. Our most recent studies demonstrated that
implanted USCs restored sphincter function by increasing
leak point pressure (LPP) in a rat model one week after
vaginal distention injury (unpublished data).
Bladder or urethral reconstruction
The ideal stem cell sources for bladder repair would i) be
able to differentiate into functional smooth muscle, uro-
thelial, endothelial, and peripheral neurocytes with high
efficiency. These promote bladder contractility and
compliance, and restore histological structures with innate
vasculature and innervation; ii) allow collection via a non-
invasive, simple, safe, and low-cost method; iii) have
universal or ‘off the shelf’ availability; and iv) generate
tissue-specific or organ-specific stem cells from the urinary
tract system. Currently, it is unknown whether such a
‘perfect’ stem cell exists. We do know, however, that
certain cell types are more favorable than others. Although
BMSCs or adipose stem cells are the most commonly used
MSCs, they have some limitations in tissue engineering
technology applications for lower urinary tract recon-
struction, such as low differentiation capacity (<5% of
urothelial cells of endodermal lineage), short lifespan
in vitro (<10 passages in BMSCs), and the need for invasive
collection procedures.
To be used successfully in tissue engineering approaches
for lower urinary tract reconstruction, USCs must be
directed to three types of bladder cells: smooth muscle,
urothelial, and endothelial cells. Via trans-differentiation,
USCs can give rise to all three types in vitro and in vivo.37,72
In addition, when both myogenically-differentiated USCs
and urothelially differentiated USCs were co-cultured on
decellularized collagen matrix (such as SIS or bladder sub-
mucosa), the urothelium and muscle layer structure in vitro
is similar to that of the bladder wall.37,72 Further cys-
toplasty experiments in animal models are needed to test
the feasibility and efficacy of USCs or the induced USCs.
In addition, we found that USCs differentiated into
podocytes and renal tubule epithelial cells in vitro and
significantly enhanced renal function after implantation of
USCs by reducing collagen deposition and inhibiting fibrosis
formation in a rodent model of chronic renal failure (un-
published data).
Future directions
To use stem cell therapy more efficiently for tissue repair or
regeneration requires enhancing angiogenesis for survival
of grafted cells, inducing innervation for functional recov-
ery, and developing more suitable biomaterials in the
future. Increasing the ratio of cell retention and improving
long-term engraftment after cell implantation will lead to
better genitourinary tissue regeneration. The grafted cells
start to die within the first week, most probably due to
ischemia, inflammation, or apoptosis due to detachment
from the extracellular matrix. It is extremely important to
increase viability of implanted stem cells early after cell
transplantation. Controlled release of exogenous angio-
genic factors, such as genetically modified stem cells,significantly increase cell retention and induce better tis-
sue formation. Because of safety concerns, use of viral
gene transfection might not be optimal.
In addition, for tubule or hollow organ tissue engineering
in urology, urothelial cells seeded on the luminal side of
scaffold are often lost during surgery, washed out via the
urine, or mechanically ejected via the urethral catheter. To
solve these problems, several methods might help: a)
using biomaterials with porous micro-structure to aid cell
retention within the scaffold; b) keeping the cell-seeding
scaffold construct wet in the culture media, and avoid
drying it out during surgery; c) inducing angiogenesis or
capillary network formation early in implantation with
angiogenic growth factors released from nanoparticles or
microbeads, adding growth factors (such as FGF2 or IGF-1)
into binding scaffolds in the site, or pretreatment of hyp-
oxic cells; and d) promoting revascularization (artery-
capillary-venous system) at the middle or late stages after
the implantation using biologically safe physical stimula-
tion, including lower-frequency electrical stimulation or
low-intensity ultrasound. These methods could extend the
lifespan of implanted cells in vivo to provide better tissue
repair with long-term release of paracrine factors and
trans-differentiation, resident cell recruitment, anti-
fibroblast formation, and anti-inflammatory and anti-
apoptotic effects of MSCs. In addition, innervation is crit-
ical to create a functional bladder. Stimulating peripheral
nerve growth into neobladder tissue might be more effi-
cacious than attempting to create neurogenic differentia-
tion of MSCs.
To achieve clinically successful results, USCs need
further investigation. Although USCs restore tissue or organ
function in rodent models, larger animal experiments are
required before cell therapy could be attempted in clinical
trials. Relevant questions include: a) What is the mecha-
nism by which USCs generate tissue repair, trans-
differentiation, or trophic effects? Is it necessary to
induce USCs to differentiated target cells in vitro, or can
undifferentiated stem cells achieve similar or better out-
comes as pre-differentiated stem cells? b) As a novel stem
cell source, can USCs be used for tissue repair and regen-
eration in non-urinary tract sites, such as skin, vessels,
heart, lung, or liver tissue?Summary and conclusions
As a novel cell source, USCs possess an excellent feasibility
and safety profile for tissue regeneration, specifically for
genitourinary tissue repair. These cells express telomerase
activity and are highly expandable, but do not induce ter-
atomas or tumors in vivo. USCs not only efficiently give rise
to podocytes, myocytes, and endothelial and urothelial
cells, they also secrete a battery of growth factors and
cytokines. Preclinical outcomes of cell therapy with USCs
have been positive in models of diabetic erectile function,
stress urinary incontinence, urethra and bladder recon-
struction, and renal insufficiency. USCs can be obtained via
a non-invasive, simple, safe and low-cost approach. Besides
genitourinary tissue repair, USCs might also be a viable cell
source for cell-based therapy in treatment of tissue defects
or diseases in other systems.
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